Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In China

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 42 to 77 days (approximately 2 months) at the time of enrollment.~2. Healthy infant as determined by medical history, physical examination, and judgment of the investigator.~Exclusion Criteria:~1. Previous vaccination with licensed or investigational pneumococcal vaccine.~2. A previous anaphylactic reaction to any vaccine or vaccine-related component.~3. Contraindication to vaccination with pneumococcal vaccines.

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 77 Days
- Healthy Volunteers: t

Study Arms:
- 7vPnC (3-, 4-, 5-, 12-Month) (Type: ACTIVE_COMPARATOR): None
- 13vPnC (3-, 4-, 5-, 12-Month) (Type: EXPERIMENTAL): None
- 13vPnC (2-, 4-, 6-, 12-Month) (Type: EXPERIMENTAL): None
- 13vPnC (3-, 5-, 12-Month) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).